Rod Humerickhouse, M.D., Ph.D.

Dr. Humerickhouse is responsible for leading Xencor’s clinical development and medical affairs strategy and execution in oncology. Before joining Xencor in April 2024, he served as vice president, hematology at Bristol Myers Squibb. In this role, he was responsible for development strategy for multiple late-stage assets, setting overall disease strategy, guiding project prioritization and informing early clinical development and business decisions. Prior to BMS, he spent 20 years in roles of increasing responsibility at Abbvie/Abbott Laboratories leading teams for VENCLEXTA® and other programs, including Bcl-2 inhibitors, VEGF TKI (linifanib) and anti-EGFR antibodies. Dr. Humerickhouse received his M.D. and Ph.D. at Indiana University School of Medicine and completed both his internal medicine training and hematology/oncology fellowship at the University of Chicago Hospitals.